Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
0.783
+0.100 (14.72%)
At close: Feb 21, 2025, 4:00 PM
0.780
-0.003 (-0.33%)
After-hours: Feb 21, 2025, 7:53 PM EST
Acurx Pharmaceuticals Employees
Acurx Pharmaceuticals had 4 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$4,108,975
Market Cap
13.22M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4 | 0 | - |
Dec 31, 2022 | 4 | 1 | 33.33% |
Dec 31, 2021 | 3 | 0 | - |
Dec 31, 2020 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ACXP News
- 3 days ago - JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors - PRNewsWire
- 6 weeks ago - Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - PRNewsWire
- 6 weeks ago - Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - PRNewsWire
- 6 weeks ago - Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI) - PRNewsWire
- 2 months ago - Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025 - Accesswire
- 2 months ago - Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications - PRNewsWire
- 3 months ago - Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook - CNBC
- 3 months ago - Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset - PRNewsWire